A Phase 1/2 Combined Dose Ranging and Randomized, Open-label, Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilization of Haematopoietic Stem Cells Into Peripheral Blood, and Subsequent Collection by Apheresis, Versus Standard Mobilization Regimens Alone in Pediatric Patients, Aged 1 to less than 18 Years, With Solid Tumours Eligible for Autologous Transplants.

Trial Profile

A Phase 1/2 Combined Dose Ranging and Randomized, Open-label, Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilization of Haematopoietic Stem Cells Into Peripheral Blood, and Subsequent Collection by Apheresis, Versus Standard Mobilization Regimens Alone in Pediatric Patients, Aged 1 to less than 18 Years, With Solid Tumours Eligible for Autologous Transplants.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Plerixafor (Primary) ; Antineoplastics; Granulocyte colony-stimulating factors
  • Indications Brain cancer; Ewing's sarcoma; Neuroblastoma; Soft tissue sarcoma; Solid tumours
  • Focus Therapeutic Use
  • Acronyms MOZAIC
  • Sponsors Sanofi; Sanofi Genzyme
  • Most Recent Events

    • 15 May 2017 Status changed from active, no longer recruiting to completed.
    • 11 Feb 2017 This trial has been completed in the Poland.
    • 02 Feb 2017 This trial has been completed in the Netherlands.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top